Investors
Board
John Öhd, M.D., Ph.D.
Chief Executive Officer
John Öhd, M.D., Ph.D.
CEO since 2020 and previously CMO since 2018
Born: 1971
Education and experience: MD, PhD. John Öhd has extensive experience in drug development and has previously worked in several different indication areas, including CNS, cancer and blood diseases. Öhd's previous qualifications include the leadership positions within the research organizations of AstraZeneca and Shire and as Chief Medical Officer at the biotechnology company Medivir.
Other current roles: Chief Scientific Officer at KDventures AB. Board Member at Umecrine Cognition AB, SVF Vaccines AB and Boost Pharma.
Holdings: 3 260 591 shares
Education and experience: MD, PhD. John Öhd has extensive experience in drug development and has previously worked in several different indication areas, including CNS, cancer and blood diseases. Öhd's previous qualifications include the leadership positions within the research organizations of AstraZeneca and Shire and as Chief Medical Officer at the biotechnology company Medivir.
Other current roles: Chief Scientific Officer at KDventures AB. Board Member at Umecrine Cognition AB, SVF Vaccines AB and Boost Pharma.
Holdings: 3 260 591 shares
Claes Lindblad
CFO & Head of IR
Claes Lindblad
CFO since 2021.
Born: 1967
Education and experience: Master of Sciences in Chemical and administrative sciences from university of Karlstad. Claes Lindblad has over 25 years of broad experience from leading positions in life science. Lindblad has previously been CFO of the Medtech company OssDsign, where he led the company's financial and administrative functions and played a key role in the company's listing on Nasdaq First North Growth Market 2019. Before that, Lindblad has held several senior positions, including as Country manager for the global and market leading Medtec company ConvaTec, and in the role of Sales director for the OTC and generic portfolio at Nycomed / Takeda.
Other current roles: None
Holdings: 79 056 shares.
Education and experience: Master of Sciences in Chemical and administrative sciences from university of Karlstad. Claes Lindblad has over 25 years of broad experience from leading positions in life science. Lindblad has previously been CFO of the Medtech company OssDsign, where he led the company's financial and administrative functions and played a key role in the company's listing on Nasdaq First North Growth Market 2019. Before that, Lindblad has held several senior positions, including as Country manager for the global and market leading Medtec company ConvaTec, and in the role of Sales director for the OTC and generic portfolio at Nycomed / Takeda.
Other current roles: None
Holdings: 79 056 shares.
Viktor Drvota, M.D, Ph.D
Chairman | CEO, KDventures AB
Viktor Drvota, M.D, Ph.D
Chairman since 2016.
Born: 1965
Education and experience: MD, PhD, Assoc Prof in Cardiology at Karolinska Institute. Viktor Drvota has over 18 years’ experience from venture capital in life sciences. Drvota was responsible for life science at SEB Venture Capital 2002–2016 and has many years of experience of board duties in biotech and medtech companies.
Other current roles: CEO of KDventures AB and Umecrine Cognition AB . Chairman of the board at Modus Therapeutics AB, Modus Therapeutics Holding AB, Umecrine Cognition AB. Board member at KDev Investments AB, UC Research AB, Dilafor AB, AnaCardio and Dilafor Incentive AB. Deputy board member at Svenska Vaccinfabriken Produktion AB.
Holdings: 0 Shares.
Viktor Drvota is independent in relation to the Company and company management but dependent in relation to the Company's major shareholders.
Education and experience: MD, PhD, Assoc Prof in Cardiology at Karolinska Institute. Viktor Drvota has over 18 years’ experience from venture capital in life sciences. Drvota was responsible for life science at SEB Venture Capital 2002–2016 and has many years of experience of board duties in biotech and medtech companies.
Other current roles: CEO of KDventures AB and Umecrine Cognition AB . Chairman of the board at Modus Therapeutics AB, Modus Therapeutics Holding AB, Umecrine Cognition AB. Board member at KDev Investments AB, UC Research AB, Dilafor AB, AnaCardio and Dilafor Incentive AB. Deputy board member at Svenska Vaccinfabriken Produktion AB.
Holdings: 0 Shares.
Viktor Drvota is independent in relation to the Company and company management but dependent in relation to the Company's major shareholders.
Pernilla Sandwall
Board Member | COO of Umecrine Cognition AB
Pernilla Sandwall
Board Member since May 2026
Born: 1963
Education and experience: Pernilla Sandwall has a MSC in Pharmacy from Uppsala University. Pernilla Sandwall has over 30 years’ experience from senior leadership roles in life sciences, including as CEO and COO in both listed and private biotech companies. She has extensive expertise in clinical development, corporate governance and capital markets, with previous roles at Merck/MSD, InDex Pharmaceuticals and WntResearch.
Other current roles: COO of Umecrine Cognition AB, Board member of MyCural and Clinical Trial Consultants.
Holdings: 0 shares.
Pernilla Sandwall is independent in relation to the Company, the Company management and the Company's major shareholders.
Education and experience: Pernilla Sandwall has a MSC in Pharmacy from Uppsala University. Pernilla Sandwall has over 30 years’ experience from senior leadership roles in life sciences, including as CEO and COO in both listed and private biotech companies. She has extensive expertise in clinical development, corporate governance and capital markets, with previous roles at Merck/MSD, InDex Pharmaceuticals and WntResearch.
Other current roles: COO of Umecrine Cognition AB, Board member of MyCural and Clinical Trial Consultants.
Holdings: 0 shares.
Pernilla Sandwall is independent in relation to the Company, the Company management and the Company's major shareholders.
Sofi Eriksson
Board Member | Key Positions within Family Offices and Wealth Management
Sofi Eriksson
Board Member since May 2026.
Born: 1961
Education and experience: Sofi Eriksson holds a BSc/Msc in Business Administration and Economics from the Gothenburg School of Economics, with major in International Finance and French. Sofi Eriksson has over 30 years of experience in senior finance and investment roles across global listed corporations, private equity-backed companies and high-growth businesses, including approximately 15 years within pharma and biotech. Sofi has extensive expertise in financial governance, M&A, value creation, capital markets and financing, with previous roles at Pharmacia/Pfizer, Sandvik, Phadia, Bambora Group and the Private Equity firm Nordic Capital, as well as Group CFO of Dentalum Group.
Other current roles: Board and Advisory roles within Family Offices and Wealth Management
Holdings: 0 shares.
Sofi Eriksson is independent in relation to the Company, the Company management and the Company's major shareholders.
Education and experience: Sofi Eriksson holds a BSc/Msc in Business Administration and Economics from the Gothenburg School of Economics, with major in International Finance and French. Sofi Eriksson has over 30 years of experience in senior finance and investment roles across global listed corporations, private equity-backed companies and high-growth businesses, including approximately 15 years within pharma and biotech. Sofi has extensive expertise in financial governance, M&A, value creation, capital markets and financing, with previous roles at Pharmacia/Pfizer, Sandvik, Phadia, Bambora Group and the Private Equity firm Nordic Capital, as well as Group CFO of Dentalum Group.
Other current roles: Board and Advisory roles within Family Offices and Wealth Management
Holdings: 0 shares.
Sofi Eriksson is independent in relation to the Company, the Company management and the Company's major shareholders.